Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,764.40
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.95
(
0.49%
)
Bitcoin
70,530.00
(
0.90%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

masterlongevity

Send PM Follow Ignore
Followers 24
Posts 2597
Boards Moderated 0
Alias Born 01/07/2004

masterlongevity

Re: DewDiligence post# 45668

Wednesday, 04/25/2007 12:38:25 AM

Wednesday, April 25, 2007 12:38:25 AM

Post# of 257262
OK. Point taken. Since Avonex is still the market leader in RRMS, even over copaxone, I think we should just use Avonex

Avonex
Tysabri
Copaxone

According to my research
Rituxan - estimated launch H1 2009
FTY720- estimated launch H1 2009


although if Rituxan data is positive in PPMS (H1 2008), i think it will be used heavily off-label


Can we combine Rituxan and FTY20 and call them new products?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now